
Personalis Inc (PSNL) Stock Forecast & Price Target
Personalis Inc (PSNL) Analyst Ratings
Bulls say
Personalis Inc. has seen a positive trajectory in its stock, with a notable 28% increase following the announcement of Medicare coverage for its NeXT Personal MRD test in breast cancer, further indicating strong demand and market validation for its products. The company has made strategic adjustments to its business operations to enhance cash flow in anticipation of reimbursement outcomes, demonstrating prudent financial management. Additionally, the partnership with large commercial entities like Tempus and Merck indicates robust growth potential, with expected sales increases for 2026 and beyond, underscoring Personalis's long-term value and market opportunity in personalized cancer therapeutics.
Bears say
Personalis Inc. faces a negative outlook primarily due to a downward revision of its revenue guidance for Q4 2025, stemming from a slowdown in the biopharma sector and logistical issues with global sample management. The anticipated revenue decline of 12% to 5% year-over-year reflects challenges in predicting sample flow for minimal residual disease (MRD) testing and delays in reimbursement approvals, potentially impacting future cash flows. Additionally, an ongoing history of substantial losses and debt on the balance sheet raises concerns about the company’s ability to achieve and sustain profitability amidst these operational hurdles.
This aggregate rating is based on analysts' research of Personalis Inc and is not a guaranteed prediction by Public.com or investment advice.
Personalis Inc (PSNL) Analyst Forecast & Price Prediction
Start investing in Personalis Inc (PSNL)
Order type
Buy in
Order amount
Est. shares
0 shares